We are a clinical stage biopharmaceutical company leveraging our two proprietary technology platforms to discover, design and develop novel, proprietary medicines for prevention, diagnosis and treatment of neurodegenerative diseases associated with protein misfolding. We have a particular expertise and focus on Alzheimer’s disease.
Our two proprietary technology platforms allow us to discover, design and develop antibodies, small molecules and vaccines. These platforms are the engines for our diverse pipeline of product candidates, which currently consists of seven therapeutic product candidates with four in clinical trials and three diagnostic candidates. Our lead product candidate is crenezumab, an anti-Abeta antibody being developed in phase 3 for Alzheimer’s disease by our collaboration partner Genentech. We believe that our multiple strategic alliances with leading industry partners like Genentech, Janssen, Piramal, Nestlé Institute of Health Sciences and Biogen provide external validation of our Company and the quality of our science.
Our Investor Center is designed to provide you with convenient access to information about our Company.
Various statements that AC Immune makes on this website about the company's future expectations, plans, and prospects constitute forward-looking statements for purposes of the safe harbor provisions under the Private Securities Litigation Reform Act of 1995. All statements other than statements of historical facts, including statements regarding our future results of operations and financial position, business strategy, product candidates, product pipeline, ongoing and planned clinical studies, including those of our collaboration partners, regulatory approvals, research and development costs, timing and likelihood of success, as well as plans and objectives of management for future operations are forward-looking statements. Many forward-looking statements can be identified by the use of forward-looking words such as “anticipate,” “believe,” “could,” “expect,” “should,” “plan,” “intend,” “estimate,” “will” and “potential,” among others. Actual results may differ materially from those indicated by these forward-looking statements as a result of various important factors.
In addition, any forward-looking statements represent the company's views only as of the date such statements are made and should not be relied upon as representing our views as of any subsequent date. While the company may elect to update these forward-looking statements at some point in the future, the company specifically disclaims any obligation to do so, even if its views change. Therefore, you should not rely on these forward-looking statements as representing the company's views as of any date subsequent the date such statements are made.
You hereby agree and acknowledge that except as expressly permitted in a written agreement with us or our affiliates, you are expressly prohibited from using the content, information and materials herein and any information provided by us in any format and/or delivery method including without limitation email, facsimile, journalistic content (the "Content") for any purpose. You are specifically prohibited from distributing, transferring, sub-licensing, transmitting, selling, repackaging, assigning, leasing, reselling, publishing or otherwise making available all or any portion of the Content herein, or any analysis or presentation based on such Content, by whatever means to any person or entity. Any unauthorized use of any Content appearing herein may violate our intellectual property rights under any intellectual property laws such as copyright laws, trademark laws, regulations and statutes and is strictly prohibited.
For more information concerning the risks the Company faces, visitors to the website should refer to the "Risk Factors" contained in the Company’s filings with the United States Securities and Exchange Commission.